RUNX1 mutation is a suspected disease in the field of blood tumours, with clinical performance being complex and often involving multiple systemic strain. Early identification and standardization of the diagnosis are essential for improving the prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
The platform can help align teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Individualised treatment plans for the treatment and management of the RUNX1 mutation associated with RUNX1 are required, typically including drug therapy, rehabilitation, regular follow-up, and multidimensional management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to the timely schedule according to the changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of the RUNX1 mutation associated with acute myeloid leukemia. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.